Categories: Market Research

Global Muscle Relaxant Drugs Market Size and Forecast 2024-2033| IdeaForge Technology Pvt. Ltd., AeroVironment Inc., SZ DJI Technology Co. Ltd., Autel Robotics, Draganfly Inc., Microdrones GmbH

The Muscle Relaxant Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Muscle Relaxant Drugs Market:

https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report

According to The Business Research Company’s Muscle Relaxant Drugs Global Market Report 2024, The muscle relaxant drugs market size has grown strongly in recent years. It will grow from $4.46 billion in 2023 to $4.83 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to shift in treatment approaches, chronic pain management, pharmaceutical innovation in drug formulations, rise in surgical procedures, expansion in physical rehabilitation practices.

The muscle relaxant drugs market size is expected to see strong growth in the next few years. It will grow to $6.55 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to multidisciplinary pain management approaches, aging population and chronic conditions, research in targeted therapies, focus on non-pharmacological pain relief, advancements in pain management therapies.. Major trends in the forecast period include advancements in side effect profiles, personalized medicine approach, research in alternative therapies, integration of muscle relaxants in pain management protocols, advent of botulinum toxin injections.

The rising geriatric population is expected to propel the growth of the muscle relaxant drugs market going forward. The geriatric population refers to older adults 65 years and beyond. Muscle relaxant drugs are used for sedating and reducing the pain of the geriatric population who are more likely to suffer from musculoskeletal disorders. For instance, in October 2022, according to the World Health Organization, a Switzerland-based international public health organization, the global population of individuals aged 60 years is projected to increase to 1.4 billion by 2022 compared to 1 billion in 2020. Moreover, 1 out of 6 people in the world will be aged more than 60 years or older by 2030. Therefore, the rising geriatric population is driving the growth of the muscle relaxant drugs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=8751&type=smp

The muscle relaxant drugs market covered in this report is segmented –

1) By Drug Type: Facial Muscle Relaxant Drugs, Skeletal Muscle Relaxant Drugs, Neuromuscular Blocking Agents

2) By Formulation: Cyclobenzaprine, Carisoprodol, Chlorzoxazone, Metaxalone, Methocarbamol, Baclofen, Tizanidine, Orphenadrine, Dantrolene

3) By Route of Administration: Oral, Injectable, Spray, Ointment

4) By End-User: Hospitals, Homecare, Speciality Clinics, Other End-Users

Product innovations are the key trend gaining popularity in the muscle relaxant drug market going forward. Major companies operating in the market are developing innovative drugs for specific medical applications, such as generic versions of muscle relaxant drugs, muscle relaxants for animals, drugs that provide flexible, customized dosing, and others, to sustain their position in the market. For instance, in June 2022, Amneal Pharmaceuticals Inc., a US-based integrated specialty pharmaceutical company, launched LYVISPAH, a baclofen oral granule (5, 10, and 20 mg) specialty product approved by the US Food and Drug Administration for the treatment of spasticity associated with multiple sclerosis and other spinal cord disorders. LYVISPAHI offers flexible, customized dosing with 5 mg, 10 mg, and 20 mg single-dose packets of granules that are used in treating muscle stiffness, spasms, and pain from multiple sclerosis. The rapidly dissolving flavored granules offer an alternative for patients with spasticity who also have difficulty swallowing pills. The product can be administered in three ways: directly into the patient’s mouth with or without water, mixed with liquids or foods, or through an enteral feeding tube.

The muscle relaxant drugs market report table of contents includes:

1. Executive Summary

2. Muscle Relaxant Drugs Market Characteristics

3. Muscle Relaxant Drugs Market Trends And Strategies

4. Muscle Relaxant Drugs Market – Macro Economic Scenario

5. Global Muscle Relaxant Drugs Market Size and Growth

26. South America Muscle Relaxant Drugs Market

27. Brazil Muscle Relaxant Drugs Market

28. Middle East Muscle Relaxant Drugs Market

29. Africa Muscle Relaxant Drugs Market

30. Muscle Relaxant Drugs Market Competitive Landscape And Company Profiles

Top Major Players: